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Abstract
Although inherited predispositions to hematologic malignancies have previously been
considered extremely rare, approximately 12 causative genes have been implicated in the last
decade. Since individuals diagnosed with leukemia have not historically been considered for
evaluation of inherited predispositions, genetic testing is underperformed in this population.
This study used focus group discussions to explore the attitudes, motivations, and barriers to
genetic testing for 23 patients with leukemia. Participants generally exhibited a positive regard
for the utility of genetic testing, and were primarily motivated by concern for their family and a
sense of altruism toward all leukemia patients. While drawbacks and barriers were difficult for
participants to identify, a few individuals cited concerns about confidentiality of genetic
information and possible discrimination based on test results. Participants unanimously agreed
that the skin punch biopsy required for genetic testing in leukemia patients would not deter their
decision to be tested. The findings from this study are valuable for guiding genetic counseling
that best meets the specific needs of leukemia patients, and future studies will analyze how these
issues are perceived by a larger and more diverse population of individuals with leukemia.
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Introduction
Germline mutations causing predisposition to acute leukemia (AL) and myelodysplastic
syndrome (MDS) have been underappreciated, especially among affected adults. Prior to 2003,
there were no clearly defined genetic etiologies underlying acute myeloid leukemia (AML),
MDS, and/or other types of leukemia outside of inherited bone marrow failure syndromes like
Fanconi anemia (1, 2). However, within the last decade, more than 12 inherited predisposition
genes have been identified in association with these malignancies (3, 4). Current data support
that between 10-29% of individuals with leukemia referred for genetic testing have germline
mutations predisposing to hematologic malignancies (5, 6). According to the 2017 Surveillance,
Epidemiology and End Results (SEER) data, there are 21,380 new AML diagnoses and 5,970
new acute lymphoblastic leukemia (ALL) diagnoses in the United States annually. Additionally,
there are an estimated 10,000 new cases of MDS in the United States each year (7).
Emerging data regarding hereditary predispositions to hematologic malignancies suggest
that MDS, AML, and aplastic anemia (AA) have the highest hereditary component, while
hereditary predispositions to B-cell ALL and chronic leukemias remain rare. Predisposition
syndromes involving autosomal dominant mutations in the genes RUNX1, ANKRD26, and ETV6
share a similar clinical phenotype, including thrombocytopenia, platelet dysfunction, and an
increased risk to develop MDS and AML (8-10). Familial MDS/AML has also been associated
with autosomal dominant mutations in DDX41, GATA2, SRP72, and CEBPA genes (11-14).
Additionally, a 700 kilobase duplication in the region of 14q32.2 that encompasses the ATG2B
and GSKIP genes has been linked to an increased risk for AML, but also to other malignancies,
including chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML)
(15). The inherited bone marrow failure syndromes (IBMFS) Fanconi anemia and dyskeratosis

2

congenita, previously well-described in the pediatric population, have also emerged as causes of
adult-onset MDS, AML, and AA, even in those who do not meet phenotypic criteria (2, 16, 17).
In addition to these genes that cause inherited susceptibility to MDS, AML, and AA,
there are also several genes identified in association with familial B-cell ALL. The PAX5 gene
exhibits a dominant predisposition to B-cell ALL with incomplete penetrance (18). While
commonly recognized as the gene implicated in Li-Fraumeni Syndrome (LFS), heterozygous
germline mutations in TP53 also cause B-cell ALL in 5% of individuals affected with LFS (19).
Additionally, the SH2B3 gene has been implicated as an autosomal recessive predisposition
locus for B-cell ALL (20).
Genetic testing for inherited predispositions to leukemia has several imperative
implications for the clinical care of affected individuals. If a germline mutation is identified,
this information can be used to guide treatment and surveillance plans, aid in donor selection for
hematopoietic stem cell transplantation (SCT), and evaluate risks for certain comorbidities and
treatment-related complications. For example, as several predisposition syndromes are
associated with increased toxicity when treated with standard doses of chemotherapy or
radiation for SCT conditioning, identification of at-risk patients can allow clinicians to provide
tailored, reduced-intensity conditioning regimens (21-23). Moreover, although HLA-matched
siblings are often regarded as ideal donors for allogeneic SCT, genetic testing helps prevent the
selection of a related donor who carries the same germline mutation as the patient, which can
potentially result in graft failure, donor-derived leukemia, and severe graft-versus-host disease
(24, 25). Detection of a familial mutation also has key implications for unaffected relatives.
Predictive genetic testing can aid in identifying individuals who may be at increased risk to
develop leukemia in their lifetimes. While there are currently no means to prevent leukemia,
identification of at-risk relatives may allow for those individuals to obtain surveillance
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bloodwork and/or bone marrow evaluation for emerging clonal disease or hematologic
malignancies (4). Additionally, identifying families with hereditary syndromes can also help
connect them with valuable resources for family counseling, psychosocial support, and family
planning.
As availability and awareness of genetic testing for inherited predispositions to leukemia
increases, much remains unknown about the behavioral and psychosocial aspects of genetic
counseling and testing in this patient population. Unlike solid tumor patient populations such as
breast and colorectal cancer, leukemia patients are entirely unexplored regarding their
knowledge, attitudes, and perceived motivations and barriers to genetic testing. After genetic
testing for predispositions to breast and colorectal cancer first became available in the early
1990s, numerous studies sought to assess attitudes towards and perceptions about genetic testing
in these two distinct populations (26-29). Common themes elicited during these studies included
feelings of guilt for passing cancer susceptibility on to children, relief from uncertainty after
learning one’s genetic information, concern for cancer risks in family members, fear of
discrimination based on genetic information, and concern for psychological distress after a
positive result. Many of these studies also sought to identify differences in genetic testing
uptake based on perceived benefits, drawbacks, and one’s own cancer risk (28-36). Unlike solid
tumor patients where genetic testing can be performed on a blood or saliva sample, genetic
testing for individuals with leukemia requires a non-hematopoietic specimen. In these
individuals, peripheral blood is contaminated by the hematologic malignancy which contains
somatic mutations and chromosomal abnormalities that can confound genetic test results. As
such, cultured skin fibroblasts are the gold standard for germline analysis and are obtained
through a skin punch biopsy procedure. This presents a potential barrier to genetic testing that is
unique to the leukemia patient population and has yet to be explored.
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This study seeks to elicit leukemia patients’ attitudes, motivations, and barriers to
genetic testing through the use of focus group discussions. Focus groups are a well-established
qualitative research methodology that can be used to identify perceptions among subpopulations
about certain experiences such as genetic testing (37). They are ideal for eliciting individuals’
attitudes and beliefs in order to design appropriate interventions for the subpopulation of interest
(38). Focus groups have been shown to serve as a fundamental tool in generating themes
surrounding attitudes towards genetic testing as well as generating focused hypotheses for
further study in these populations (28, 29, 32, 35, 39-41). A deeper understanding of the
attitudes, motivations, and barriers to genetic testing in the leukemia patient population will
impact patient care by allowing clinicians to address the specific concerns and needs of this
unique population.
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Methods
Participants and Recruitment
Individuals were eligible to participate in a focus group if they were 18 years or older,
English-speaking, and had a current or previous diagnosis of any type of leukemia. Potential
participants were identified by screening the daily clinic census for the Leukemia Center at The
University of Texas M.D. Anderson Cancer Center (MDACC) in Houston, Texas. Individuals
who were at the clinic on the day of a scheduled focus group were randomly selected and
contacted by phone to recruit for focus group participation the week before the scheduled
meeting.
Procedures and Setting
Institutional review board approval was obtained. Verbal informed consent was obtained
from all study participants by the principal investigator (TB). Each focus group had a minimum
of 2 and a maximum of 5 participants. Focus groups were conducted between November 2017
and February 2018. Each discussion generally lasted 20 to 45 minutes and was facilitated by the
principal investigator (TB). A second investigator (SB) was present at each focus group to
record notes about the discussion and nonverbal cues from the participants.
The facilitator provided a description of the study, measures used to protect
confidentiality, and instructions for effective focus group participation (Supplemental Document
1). Participants completed an anonymous demographics survey. A brief introduction was given
on cancer genetics and genetic testing for hereditary leukemia. The facilitator utilized a script to
guide the discussion. Open-ended questions were asked to assess attitudes toward, motivations
for, and barriers to genetic testing for hereditary leukemia (Supplemental Document 1).
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Data Analysis
All discussions were recorded and transcribed verbatim by a transcription service. The
transcripts were then independently coded by two study investigators (TB, SB) to identify
themes. A total of 173 thematic codes were used to code each transcript. The independently
coded transcripts were subsequently compared using line by line analysis and found to have an
inter-rater reliability (IRR) of 99.4%. Coding and analysis of themes was conducted through the
qualitative data analysis and research software program, ATLAS.ti. Descriptive statistics were
utilized to describe participant demographics.
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Results
Participant Characteristics
Table 1 summarizes the demographic characteristics of the focus group participants. The
sample included 6 women and 17 men with an average age of 63 years (range 30-84 years). The
majority of participants self-reported as White/Non-Hispanic (78%), followed by 9% AfricanAmerican, 9% Hispanic, and 4% Asian. Most participants (39%) had a diagnosis of chronic
lymphocytic leukemia (CLL), followed by 22% with AML, 13% with CML, 13% with MDS,
and 9% with ALL. One individual (4%) reported a diagnosis of essential thrombocytosis (ET).
The majority of participants had at least a bachelor’s degree (57%) and a household income
greater than $100,000 USD per year (39%). Additionally, most participants reported no family
history of leukemia (87%) and had not had genetic counseling or genetic testing (91%) for nonhematologic cancer.
Table 1: Demographic Characteristics (n=23)
Variable
Mean age (years) (range)
Gender
Female
Male
Race/Ethnicity
White
Hispanic
African American
Asian
Education
High school or GED
Some college
Associate’s degree
Bachelor’s degree
Doctorate or post-graduate

No. of
participants
(%)
63 (30-84)
6 (26)
17 (74)
18 (78)
2 (9)
2 (9)
1 (4)
4 (17)
5 (22)
1 (4)
8 (35)
5 (22)
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Household income
Not disclosed
2 (9)
<$20,000
2 (9)
$20,000 – 49,999
3 (13)
$50,000 – 74,999
4 (17)
$74,000 – 99,999
3 (13)
>$100,000
9 (39)
Leukemia diagnosis
AML
4 (17)
ALL
2 (9)
MDS
3 (13)
CML
3 (13)
CLL
9 (39)
Other
2 (9)
Family history of leukemia
No
20 (87)
Yes
3 (13)
Previous genetic counseling for non-hematologic
cancer
No
21 (91)
Yes
2 (9)
Previous genetic testing for non-hematologic cancer
No
21 (91)
Yes
2 (9)
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic
syndrome; CML: chronic myeloid leukemia; CLL: chronic lymphoblastic leukemia.

Motivations for Genetic Testing
At each focus group, participants were provided a short explanation of genetic
counseling and genetic testing for hereditary predispositions to hematologic malignancy,
including a description of genes, patterns that would suggest an inherited predisposition,
and the genetic testing process (Supplemental Document 1). Focus group participants
were then asked a series of questions to elicit how they would feel if they were offered
genetic testing and what they perceived as their primary motivations for genetic testing.
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Concern for Children and Family Members
The questions elicited a strong theme of concern for children as well as concern
for extended family, which consistently emerged in every focus group. These two
responses were the most frequently coded themes, together appearing 69 times out of
754 total coded responses (9.2%). Participants expressed concerns regarding the risk of
passing a predisposition to leukemia on to their children, as well as the risk for other
relatives to receive a leukemia diagnosis. For instance, one woman shared, “I have two
daughters, and I would want to know if what I have, I could have passed on to them.”
Participants conveyed a desire for their children and other relatives to obtain genetic
testing to assess their risk status. One participant stated, “I think that if I was tested, I
would hope that eventually too my kids would be tested. I think that the earlier that you
can catch any illness or any disease, the better off you are.” Several individuals shared
that they would never want to see their loved ones go through such a devastating
diagnosis. “I would want to see if there is something lying there that could go to my
niece or nephews or if it could even go to my sister, and if we could prevent it, I would
definitely… I don’t want [my sister] to go through what I went through last year by any
means.” As such, they were often motivated by the hope that obtaining genetic
information could empower their families with an awareness of their cancer risk and
allow them to take measures to detect leukemia early or preferably avoid the disease
altogether:
“I would definitely want them to have a heads up. I mean some things can't be
prevented, but if there is any preventative steps that could be taken, then I would
really like my family members to know.”
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“My wife has a predisposition for breast cancer on her mother’s side of the
family. So, she knows that, so then she takes extra precautions to be safer. So, I
mean if I could do that for my family, I would love to.”
Altruism
Participants also expressed altruism, or a desire to obtain genetic testing to contribute to
research and benefit all future leukemia patients, as a motivation for undergoing genetic testing.
This theme appeared 20 times out of 754 total coded responses (2.7%). For example, one
individual shared, “I would definitely do it. Just if I can help any person, that makes it
worthwhile for me.” Multiple participants expressed a desire that their participation in genetic
testing would contribute to the growing body of knowledge about the etiology of leukemia as
well as the development of new treatments and potential cures. For instance, these two
individuals who shared the following:
“I think that that’s actually the way that cancer treatment is going to [get] better
is through genetic testing.”
“I mean if there is further research down the road that you can be a participant in
that may help someone else, even if it’s not even with your immediate family. If
it could help somebody else’s family, I mean it’s well worth it.”
Participants were especially communicative of a willingness to do anything to help prevent
future patients, not just their relatives, from enduring similar hardship in their lives due to a
leukemia diagnosis. Many expressed a sentiment similar to this participant who stated, “You
know, if I can participate in some way that paves the road for somebody else to have an easier
life, then I’m all for it.” Overall, a strong desire to improve circumstances and leukemia
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treatments for future generations, including both related and unrelated individuals, was a
common theme in most focus group discussions.
Curiosity Regarding Personal Genetic Health Information
Although not raised as frequently as the above themes, several participants reported
motivation for genetic testing in order to learn about their risks for future cancer diagnoses (two
individuals), to identify the cause of their leukemia (three individuals), or to satisfy a general
curiosity about their genetic information (three individuals). For example, one gentleman
explained that he wanted testing “to see if I have a tendency for other cancers […] Any other
cancers lurking about and hiding, waiting to pop up.” A few participants expressed that their
motivation would increase if there was clear clinical actionability, either for their current
treatment or the prevention of future diagnoses: “The only part about that that makes any sense
to me is if there is something to be done as a result of knowing in advance that you’re
predisposed.” Regardless of their personal motivations, all 23 participants (100%) expressed a
positive intent to have genetic testing. Some individuals felt eager to pursue testing right away,
including one participant who stated, “Where is the line? Do you want me to sit down [for the
test] right now?”
Drawbacks and Barriers
Participants were also asked to identify potential barriers or drawbacks to genetic testing,
including issues they could imagine for themselves as well as for others. In all seven focus
groups, participants consistently struggled to identify drawbacks or barriers to genetic testing,
providing responses such as “there’s nothing that I can think of” and “I’m not concerned about
it.” The limited drawbacks they identified included issues regarding confidentiality of the data
and discrimination. Participants voiced general concerns surrounding negative impacts to
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insurance coverage, increased premium costs, and ineligibility for health and life insurance. One
gentleman shared his concern, stating: “There is also still the open question of what insurance is
going to be allowed to do with the information, and that we don’t know.” A few individuals
expressed worries about the potential lack of privacy and security of genetic testing results in
the medical record, while only one individual mentioned uncertainty about employment
discrimination:
“We don’t know if it can be used for employment decisions. We don’t know if
it’s going to make people less eligible for insurance, and we certainly don’t know
about security of that information. So all of those things to me create concerns.”
“I think that everyone is kind of worried about is the privacy of any information
that is passed between you and your doctor.”
Two participants suggested drawbacks unrelated to the issues of confidentiality and
discrimination. One gentleman deliberated whether his family would feel burdened or worried
by positive results, saying, “The question is, would they worry about [positive results] all of the
time? I mean we know that there are people that do that.” Another woman expressed worry
about her genetic testing results being shared with anyone “who has any effect over whether [I]
get treatment or how it’s treated or whether you’re a candidate or not.”
Participant responses when asked to identify potential barriers to genetic testing were
also much less robust. Most responses in this category were only voiced by one or two
participants. Two individuals shared that they felt less interested in genetic testing simply due to
their older age. They felt that knowledge of their genetic information would have less utility for
them at this stage in their life. One gentleman elaborated that although his older age currently
acted as a deterrent, he may have been more interested in testing at a younger age for family
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planning purposes: “If I was younger and planning a family, you know. I would definitely
count that as a good reason. But since I’m almost elderly, it doesn’t matter.” Conversely, a
participant in another focus group explained that younger age would have been a deterrent for
him based on employment and insurance discrimination concerns, whereas his older age
concerned him less and would not deter him from pursuing genetic testing. Another male
participant felt that his perceived barriers would be particularly influenced by his children. After
sharing that his decision to be tested would be based on whether his two children wanted him to
have testing, he explained, “If my kids didn't want me to do it because they didn't want the data
to be in the system, that certainly could deter me… If one of them wants to know and the other
one doesn’t, then we’ll have to figure that one out too. If one of them is worried about the
security of data and the other one isn't, we’ll have one of those little family meetings.”
Several other potential barriers were proposed only once by various individuals. These
included the potential inconvenience of testing, uncertainty about benefits, and limited clinical
actionability. For instance, one gentleman explained, “Basically, you want to know if there is
something that you can do about it. If there is nothing that you can do about it, I’m probably not
that interested in knowing.” Another individual proposed that some people may desire to not be
informed about their genetic information, preferring to leave their situation to fate: “Some
people just don’t want to know. I think they kind of live blindly. I’m not that person, but I mean
I’m sure that there are people that would rather just say whatever happens, happens.”
The most prominent response when participants were questioned about barriers and
drawbacks to genetic testing was that there simply were none. In fact, 12 participants explicitly
stated that they could not identify any deterrents at all, sharing thoughts such as, “I don’t think
that there would be a real reason why you shouldn’t [pursue genetic testing].”
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Table 2: Thematic Codes (total responses = 754)
Theme
Motivations
Concern for children
Concern for family
Altruism for all leukemia patients
Prevention and early detection
Desire for genetic awareness in relatives
Drawbacks and Barriers
Concerns about privacy/security
Negative impacts to insurance coverage
Less interest in testing due to older age
Children not wanting testing or results
Burden on relatives due to test results

Frequency (%)
43 (5.7)
26 (3.5)
20 (2.7)
19 (2.5)
13 (1.7)
13 (1.7)
12 (1.6)
4 (0.5)
4 (0.5)
3 (0.4)

These are the top five most frequent themes for the categories of Motivations and Drawbacks and Barriers. Note
the frequency differences between the two categories.

Perceptions Regarding Skin Biopsy
Focus group participants unanimously agreed that the skin biopsy procedure would not
be a deterrent to genetic testing. Each time they were directly questioned about having a skin
biopsy for genetic testing, participants would often laugh and explain that they have experienced
far more painful and difficult procedures as part of their leukemia treatment:
“I don’t have any problem. I’ve gone through 12 bone marrow biopsies. As
many times as I’ve been stuck, you know. So, I mean it doesn’t matter.”
“I get a bone marrow biopsy every other time here. I mean I could probably do
the skin thing myself (laughing). Just tell me how many square inches you want,
and I’ll give it to you.”
Some participants openly disclosed that they had previous experience with a skin biopsy.
However, regardless of whether or not they had previous experience with the procedure, their
view that it would not impact their testing decision remained the same.
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Overall, motivations for genetic testing were among the most robustly developed themes
throughout all seven focus groups. This is in contrast to themes related to drawbacks and
barriers, which participants overtly expressed were difficult to identify. Accordingly, drawbacks
and barriers appeared less frequently and were less pervasive throughout the focus group
discussion transcripts.
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Discussion
This study sought to identify the attitudes, motivations, and barriers to genetic testing for
hereditary hematologic malignancies in the leukemia patient population. The majority of focus
group participants were white males over the age of 50 with a high education level and an
annual income of $75,000 USD or more. Moreover, most participants had chronic leukemia.
The focus group discussions highlighted that leukemia patients were able to readily identify
motivations for genetic testing, which most often included concern for children and family as
well as altruism for all leukemia patients. On the other hand, they struggled to identify
drawbacks and barriers and, as a result, these themes were less developed.
For most participants, the information provided during the introduction to the focus
group discussion was the first time they were made aware of the hereditary component to
leukemia. In fact, four participants distinctly recalled asking their healthcare provider about a
hereditary component to their diagnosis and being told that such information was still not
known. Despite a lack of previous knowledge about genetic predispositions to leukemia,
participants were able to recognize the impact that their personal genetic information could have
on their lives and families.
Overall, a positive regard for genetic testing was ubiquitous throughout all seven focus
groups. Participants frequently articulated a view that testing is beneficial because it has the
potential to help their children and extended relatives as well as other leukemia patients. They
largely agreed that the information provided by testing results can have important implications
for their family, especially if the results are positive. Participants recognized that genetic testing
could be used as a tool to identify at-risk relatives and expressed that they would inform their
family members if a mutation was detected. In general, a desire to identify a genetic
predisposition and promote genetic awareness among relatives was commonly expressed. They
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conveyed hope that these proactive measures could help prevent disease or lead to earlier
diagnosis in their loved ones. It is interesting to note that the thematic code for concern for
family frequently co-occurred with the codes for prevention and early detection in the
discussion transcripts. These themes commonly emerged together even though the information
provided during the focus group introduction did not allude to the possibility of prevention or
early detection in relatives. Additionally, while a few participants shared that they felt autonomy
was important for each relative’s personal genetic testing decision, several discussed that they
would actively encourage their family members to be tested. These findings are consistent with
focus group studies in the solid tumor patient populations (28, 29, 32, 35).
Genetic testing was also commonly viewed as an important tool for gaining knowledge
about the etiology of leukemia and contributing to the advancement of leukemia research. This
was underscored by a strong sense of altruism for all leukemia patients, both present and future.
Many individuals shared stories about the devastating effects of their disease, and these
experiences seemed to drive their motivation to obtain genetic testing with the hope to prevent
leukemia or at the very least improve diagnostic and treatment techniques for future generations.
There was often a sense of agreement among participants that they would not wish a leukemia
diagnosis on anyone, whether they were family members, friends, or strangers. Accordingly,
several individuals expressed great willingness to contribute to leukemia research through
genetic testing. Interestingly, a strong sense of altruism has also been reported among focus
group participants in the breast cancer population, but not readily observed in focus groups
among patients with colorectal cancer (28, 32).
While the above themes were robustly developed, there were several motivations that
were expressed with less regularity. These motivations were all issues that focused more on the
self than other people. This included issues such as a desire to pinpoint a cause for one’s
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leukemia and to learn about one’s risk for other cancer diagnoses. A valuable observation here
is that participants tended to communicate these self-oriented motivations with much less
frequency than motivations oriented towards helping relatives and future leukemia patients.
Throughout all seven discussions, there was a generalized inability to recognize
drawbacks and barriers to genetic testing. While some participants were able to voice limited
concerns, the frequency and depth of these responses were less robust than the perceived
motivations for genetic testing in our analysis. One of the only issues proposed by more than
one or two participants was a concern for the confidentiality of genetic testing data and
discrimination based on positive test results. While this theme has also been identified in similar
investigations with the breast and colorectal cancer populations, it is a more predominant and
well-developed theme in these studies (28, 29, 32). Interestingly, a focus group study conducted
by Ramsey et al. also reported participants who experienced similar difficulty with imagining
potential drawbacks and barriers. However, when later presented with specific information
regarding the risks and implications of genetic testing, some participants viewed these as
drawbacks or barriers and felt more reluctant to have testing (35). Future studies in the leukemia
population should assess how patients feel about the risks and implications of genetic testing
after being given more specific information on this subject. Such an approach was not utilized in
this study, as the investigators wished to ascertain which issues would arise organically without
introducing ideas. Outside of the subject areas of confidentiality and discrimination, participants
were unsuccessful in consistently identifying other drawbacks or barriers. For example, only
one gentleman in the present study discussed possible burden or distress on relatives due to
positive genetic testing results, while previous studies in solid tumor populations have identified
this as a more common concern (28, 29, 32). Other drawbacks and barriers seen in previous
studies which were not raised by participants in this study include topics such as the cost of

19

genetic testing, feelings of guilt after learning that cancer susceptibility has been passed to
children, and the potential for psychologic distress in oneself or one’s relatives (28, 29, 32).
A unique and important finding of this study was the participants’ universal acceptance
of the skin biopsy procedure that is necessary for genetic testing in the leukemia patient
population. One hundred percent of participants agreed that this procedure would not impact
their decision to be tested. Although reason would suggest that a skin biopsy could be a
significant deterrent to testing in other patient populations, the participants in this study were
adamant that it would pale in comparison to other procedures that are part of their routine care,
especially bone marrow biopsies. Of note, participants with no previous experience with skin
biopsies did ask several questions about the logistics of the procedure, including where on the
body is the skin taken from, how large of a skin sample is retrieved, and whether the test can be
conducted when the patient has low platelet counts. Still, participants unanimously voiced a
willingness to undergo the procedure. This suggests that as long as the patient’s questions about
the procedure are addressed, skin biopsy is not likely to be a deterrent to genetic testing in this
patient population.
Participants raised a number of appropriate questions throughout the focus group
discussions. The majority of their questions pertained to logistics of the skin biopsy procedure,
as noted above. Outside of this topic, several other types of questions were raised by only one or
two individuals. These included inquiries about the reliability and validity of genetic test results,
how long testing has been available, and what clinics offer testing. One participant also asked
about the penetrance of hereditary hematologic malignancy syndromes while two others
inquired about preventative options and/or next steps after positive predictive testing in their
children. Another individual wondered whether someone with a bone marrow transplant can
have genetic testing. While the majority of these questions were posed only once and did not
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present as an overarching theme, all of them were pertinent to genetic testing for leukemia
patients and illustrate the types of questions that could be asked by these individuals in a typical
genetic counseling session.
To our knowledge, this represents the first study to explore the attitudes, motivations,
and barriers to genetic testing for inherited hematologic malignancies among patients with
leukemia. One of the primary limitations of this study was the relative homogeneity of the focus
group participants in terms of age, gender, race/ethnicity, education, and income. While the
socioeconomic background of our participants is representative of the patient population
undergoing treatment at M.D. Anderson, this sample is not representative of all leukemia
patients. Further research is needed to assess whether these views are reflective of a larger
sample of leukemia patients from more diverse backgrounds. Additionally, the conclusions
drawn from this study are subject to a selection bias. Participants’ willingness to attend the
focus group suggests a desire to participate in research, which would provide an inclination for
these individuals to express positive regard and intent for genetic testing as well as an altruistic
outlook. Another limitation of this study was the size of some of the focus groups. Most of the
discussions included three to five participants, but one discussion had only two participants.
While the ideal focus group size has not been established, experts suggest that it is practical to
have 4-12 participants per group (38). Lastly, most participants (91%) had no previous
experience with a genetic counselor. As such, these individuals were only able to discuss topics
that they could imagine on their own, which may have limited the findings of this study.
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Conclusions
In summary, our focus group discussions revealed that participants held a positive regard
for genetic testing, and were primarily motivated by concern for their family and a sense of
altruism. While drawbacks and barriers were more difficult for participants to identify, a few
individuals cited concerns about confidentiality of genetic information and discrimination based
on test results. Participants also unanimously agreed that the skin punch biopsy required for
genetic testing in leukemia patients would not deter their decision to be tested. As focus groups
studies are utilized to identify and describe issues of importance specific to the participants, the
conclusions drawn from this study cannot be used alone to extrapolate to the entire population
of interest. Future studies on this subject should analyze how these motivations and barriers to
genetic testing are perceived by a larger and more demographically diverse sample of leukemia
patients.
As genetic testing for inherited hematologic malignancies becomes progressively more
available, it will provide important information for the treatment of an increasing number of
leukemia patients. The knowledge gained from this study and future studies will be paramount
in providing genetic counseling that meets the needs of leukemia patients. Our current data
suggest that this population may not be significantly dissimilar from solid tumor populations.
Although leukemia patients seen in the genetic counseling setting may be able to readily
recognize benefits to testing, they likely need education regarding the risks and implications of
testing, as these issues could be perceived as potential drawbacks or barriers. Additionally,
while the skin biopsy may not be a deterrent to testing for patients with leukemia, they may
raise logistical questions about the procedure that could impact their decision undergo genetic
testing.
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Appendix
Supplemental Document 1: Focus Group Discussion Guide
Introduction:
Thank you for agreeing to participate in today’s focus group discussion. The purpose of
this informal discussion is to learn more about your opinions and feelings about genetic testing
for leukemia. Please feel free to share as much or as little as you would like. There are no right
or wrong answers, so please answer by giving information that best describes your opinions and
thoughts.
I would like to remind everyone that everything you say here today is completely
confidential. We will be recording the discussion so we may capture your thoughts exactly as
you say them. However, we will not be using any names during the discussion. Please be sure to
speak loudly so that the recorder can capture your thoughts.
In order to get the discussion started, I want to give you some background information
on genetic testing for leukemia. This is a very new field that many people have not heard about
yet. We will start with a brief science lesson. Our bodies are made of billions of cells and inside
each of these cells is DNA, which contains the genetic instructions that tell our body how to
grow and develop. DNA is made up of thousands of genes. Each gene contains specific
instructions that help the body perform a specific job. For example, some genes determine eye
or hair color. Other genes contain instructions to help our body fight off cancer. When there is a
change in a gene, called a mutation, this can cause the instructions in that gene to be incorrect.
Without the correct instructions, a gene that helps the body fight off cancer may not do its job
properly. When this happens, that person has a higher chance to develop certain cancers in their
lifetime. You may have previously heard about something very similar to this with breast cancer
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and the BRCA gene. Since genetic information is passed from parents to children, we often find
that mutations in genes like BRCA run in families.
Multiple gene mutations have recently been found to cause different types of leukemia to
run in families. Genetic testing has become available for these genes. This testing allows us to
take a close look at a person’s genes to see if someone has a mutation that causes an increased
chance for them to develop leukemia. Typically, genetic testing is done by collecting a blood or
saliva sample and sending that sample to the lab. Since leukemia is a cancer that occurs in the
blood, there are cancer cells in the blood that can confuse the genetic testing results. As a result,
genetic testing must be done through a skin biopsy for people with leukemia. A skin biopsy is
the same process as having a mole removed by a dermatologist and involves numbing the skin
and taking a small piece, smaller than the size of a pencil eraser, which is then sent to the lab for
genetic testing. As I mentioned earlier, our discussion today is meant to learn more about your
thoughts surrounding genetic testing for genes that cause increased risks for leukemia. We hope
to use your thoughts and feedback in order to improve the care of leukemia patients who may
have genetic testing in the future. Let’s begin.
Questions:
1) After learning that leukemia can run in families, what does that make you think about?
Probe: How does that make you feel?
Probe: Is this the first time you have heard that leukemia can be hereditary?
2) Using your own words, describe how you would feel if you were offered genetic testing
to see if your diagnosis of leukemia had a genetic cause, or if leukemia runs in your family.
Probe: Imagine you had genetic testing and your results were positive for a genetic
mutation. How would that make you feel?
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Probe: Imagine you had genetic testing and your results were negative. How would that
make you feel?
3) Describe what, if anything, may prevent you from wanting to have genetic testing.
4) Even if they may not apply to you personally, describe any other possible drawbacks you
could imagine to genetic testing.
5) If you did want to have genetic testing, why would you want to have it?
6) Even if they may not apply to you personally, describe any other potential benefits you
could imagine to genetic testing.
7) If applicable, describe how your opinions have changed as you have discussed potential
drawbacks and benefits with the other participants today.
8) After learning that genetic testing for leukemia patients requires a skin biopsy, how does
that make you feel?
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